Vivus (VVUS) shares had a bounce this morning by the encouraging announcement of round two of late-stage data on avanafil, a erectile dysfunction drug. Within 15 minutes of two doses, avanafil showed significant improvements of erectile function and intercourse from men with diabetes.
There have not been any serious adverse effects reported during the trial. Researchers have reported over 60% of the men taking the 200mg dose where able to achieve sufficient erections for intercourse following treatment.
Vivus Chief Executive Leland Wilson said “This is the second Phase III study in which avanafil demonstrated efficacy, fast onset-of-action and was well tolerated,” said . ED is a common occurrence among men with diabetes Wilson added.
Vivus is also being closely watched on progress Qnexa, an obesity drug that is also shown to lower blood pressure which has two more late-stage trials to complete a trial cycle that will enlist a total of some 1,300 patients.